Alloplex Biotherapeutics has filed a notice of an exempt offering of securities to raise $25 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Alloplex Biotherapeutics is raising $25,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Francescopaolo Borriello played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Alloplex Biotherapeutics
Alloplex Biotherapeutics is dedicated to exploring the higher order combinatorial space of immunomodulators to develop an effective anti-tumor vaccine. This approach is applicable to all tumor types and is particularly suited to combinations with checkpoint inhibitors. Alloplex is a private company and currently supported by angel investment.
To learn more about Alloplex Biotherapeutics, visit http://www.alloplexbio.com/
Contact:
Francescopaolo Borriello, Chief Executive Officer
857-272-1214
https://www.linkedin.com/in/frankborriello/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.